Company Profile
SAB Biotherapeutics Stock Price, News & Analysis
- Ticker:
- SABS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.44 USD (-1.99%)
Close
Last updated: July 27, 2026
266M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, SABS closed down 1.99% at $3.44. No new same-company headline was identified in the current news window.
Company overview
Business overview
SAB Biotherapeutics is a biopharmaceutical company focused on human polyclonal antibodies and immune therapy. Its platform aims to create broad immune responses for infectious and inflammatory diseases.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, SAB sits in specialty biotechnology.
Business Model Characteristics
The company depends on platform validation, clinical data, and the ability to turn antibody science into a commercial franchise.
Position Within the Biotechnology Landscape
SAB is a platform immunology name whose valuation depends on translational and strategic milestones.
Future catalysts
The main thing to watch at SAB Biotherapeutics is SAB-142. The update that sharpened the story was Continued site activation in registrational SAFEGUARD trial of SAB-142. That is the part of the story investors will probably keep circling back to.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
- 02
- 03
- 04
- 05
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
AVTX · Source: Avalo Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of SAB Biotherapeutics (SABS)?
SAB Biotherapeutics (SABS) most recently closed at 3.44 USD, a -1.99% move versus the previous session.
What is the market cap of SAB Biotherapeutics (SABS)?
SAB Biotherapeutics currently has a market capitalization of 266M USD on BioPharmSignal.
What does SAB Biotherapeutics do?
SAB Biotherapeutics is a biopharmaceutical company focused on human polyclonal antibodies and immune therapy. Its platform aims to create broad immune responses for infectious and inflammatory diseases.
On which exchange is SABS stock listed?
SAB Biotherapeutics (SABS) is associated with NASDAQ, United States, Biopharma.
What is SAB-142?
The main thing to watch at SAB Biotherapeutics is SAB-142.
Which conditions is SAB Biotherapeutics targeting with SAB-142?
The main thing to watch at SAB Biotherapeutics is SAB-142.
How does SAB Biotherapeutics describe recent progress with SAB-142?
The main thing to watch at SAB Biotherapeutics is SAB-142.
What is Biotherapeutics?
SAB Biotherapeutics is a biopharmaceutical company focused on human polyclonal antibodies and immune therapy.